Clinical Decision Support Software: A Key Tool for Optimizing Population Health Level Pharmacogenomics Programs | PGx For Pharmacist

Episode Description: On this episode, Dr. Jeffrey Shaman, Chief Science Officer at Coriell Life Sciences, and I discuss the importance of population health level pharmacogenomics versus one time pharmacogenomics tests and how clinical decision support software that integrates pharmacogenomics data into patients’ medication therapy management is a key tool to optimize population health level pharmacogenomics programs. References: 1. Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program https://www.mdpi.com/2075-4426/12/3/421 2. Idiopathic Symptoms Resolved by Pharmacogenomics-Enriched Comprehensive Medication Management: A Case Report https://www.cureus.com/articles/81096-idiopathic-symptoms-resolved-by-pharmacogenomics-enriched-comprehensive-medication-management-a-case-report 3. Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry https://www.coriell.com/resources/consequences-of-cyp2d6-copy-number-variation-for-pharmacogenomics-in-psychiatry/ 4. The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978656/ 5. ASP Establishes March 24th as National Adverse Drug Event Awareness Day https://www.stopadr.org/blog/asp-establishes-march-24-as-national-adverse-drug-event-awareness-day-launches-awareness-campaign Guest’s Bio: Jeffrey A. Shaman, PhD, MS, is the Chief Science Officer at Coriell Life Sciences (CLS), an international leader in precision medicine. Leveraging extensive experience in genetics and pharmacology, he is a leading expert in the rapidly evolving field of pharmacogenomics (PGx), the study of how an individual’s DNA impacts his or her response to medication. Most importantly, Dr. Shaman plays a critical role in bridging the gap between genetic science and clinical application. This includes translating decades of cutting-edge genetic research into actionable insights on the safest and most effective medications for individuals based on their unique DNA and dozens of other factors. Driven to advance public health, Dr. Shaman is focused on enabling the delivery of personalized medicine at scale and empowering the most precise medical care worldwide. He consults with large employers, public and private payer organizations, healthcare systems, academic institutions, and laboratories around the globe, advising them on how to eliminate trial-and-error prescribing, improve population health, and control rising healthcare costs Dr. Shaman is dedicated to setting the industry standard for PGx and pioneering new advancements in the field. Along with his team, he actively researches and presents findings in top peer-reviewed journals and at leading industry events. He is an active member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community, Personalized Medicine Coalition (PMC), Pharmacogenomics Global Research Network (PGRN), and other organizations. Dr. Shaman holds a doctoral degree from The Johns Hopkins University School of Medicine in Pharmacology and Molecular Sciences, where his research centered on DNA, epigenetics, and nuclear structure and function. He earned his Master of Science degree from The University of Medicine and Dentistry of New Jersey in Cell & Developmental Biology. Dr. Shaman held a faculty position at the University of Hawai‘i Institute of Biogenesis Research before serving a fellowship at Harvard Medical School and implementing a translational research program at Beth Israel Deaconess Medical Center and the Bedford Stem Cell Research Foundation. Learn more about your ad choices. Visit megaphone.fm/adchoices